| Entry |
| ||||
|---|---|---|---|---|---|
| Name | Cenobamate (USAN/INN); Xcopri (TN) | ||||
| Product | XCOPRI (SK Life Science) | ||||
| Formula | C10H10ClN5O2 | ||||
| Exact mass | 267.0523 | ||||
| Mol weight | 267.6717 | ||||
| Structure |  | ||||
| Class | Metabolizing enzyme substrate DG01638 CYP2A6 substrate DG02919 CYP2B6 substrate DG01639 CYP2C19 substrate DG02855 CYP2E1 substrate DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate DG02925 CYP3A5 substrate DG02924 UGT substrate DG03189 UGT2B4 substrate DG03190 UGT2B7 substrate | ||||
| Remark |
| ||||
| Efficacy | Analgesic, Antiepileptic | ||||
| Comment | Treatment of partial-onset seizures | ||||
| Target | GABR [HSA:2554 2555 2556 2557 2558 2559 2560 2561 2562 2563 2564 2565 2566 2567 2568 55879] [KO:K05175 K05181 K05184 K05185 K05186 K05189 K05192] SCN1A [HSA:6323] [KO:K04833] SCN2A [HSA:6326] [KO:K04834] SCN3A [HSA:6328] [KO:K04836] SCN4A [HSA:6329] [KO:K04837] SCN5A [HSA:6331] [KO:K04838] SCN8A [HSA:6334] [KO:K04840] SCN9A [HSA:6335] [KO:K04841] SCN10A [HSA:6336] [KO:K04842] SCN11A [HSA:11280] [KO:K04843] | ||||
| Pathway |
| ||||
| Metabolism | Enzyme: UGT2B7 [HSA:7364], CYP2E1 [HSA:1571], CYP2A6 [HSA:1548], CYP2B6 [HSA:1555]; UGT2B4 [HSA:7363], CYP2C19 [HSA:1557], CYP3A4 [HSA:1576], CYP3A5 [HSA:1577] | ||||
| Interaction | |||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] N NERVOUS SYSTEM N03 ANTIEPILEPTICS N03A ANTIEPILEPTICS N03AX Other antiepileptics N03AX25 Cenobamate D11150 Cenobamate (USAN/INN) <US> USP drug classification [BR:br08302] Anticonvulsants Anticonvulsants, Other Cenobamate D11150 Cenobamate (USAN/INN) Drug groups [BR:br08330] Metabolizing enzyme substrate DG01638 CYP2A6 substrate D11150 Cenobamate DG02919 CYP2B6 substrate D11150 Cenobamate DG01639 CYP2C19 substrate D11150 Cenobamate DG02855 CYP2E1 substrate D11150 Cenobamate DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate D11150 Cenobamate DG02925 CYP3A5 substrate D11150 Cenobamate DG02924 UGT substrate DG03189 UGT2B4 substrate D11150 Cenobamate DG03190 UGT2B7 substrate D11150 Cenobamate Target-based classification of drugs [BR:br08310] Ion channels Ligand-gated ion channels GABA (ionotropic) GABR D11150 Cenobamate (USAN/INN) <US> Voltage-gated ion channels Sodium channels SCN1A D11150 Cenobamate (USAN/INN) <US> SCN2A D11150 Cenobamate (USAN/INN) <US> SCN3A D11150 Cenobamate (USAN/INN) <US> SCN4A D11150 Cenobamate (USAN/INN) <US> SCN5A D11150 Cenobamate (USAN/INN) <US> SCN8A D11150 Cenobamate (USAN/INN) <US> SCN9A D11150 Cenobamate (USAN/INN) <US> SCN10A D11150 Cenobamate (USAN/INN) <US> SCN11A D11150 Cenobamate (USAN/INN) <US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D11150 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D11150 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D11150 Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D11150 | ||||
| Other DBs |
| ||||
| KCF data | ATOM 18 1 C8x C 10.6400 -26.0400 2 C8x C 10.6400 -27.4400 3 C8x C 11.8524 -28.1400 4 C8y C 13.0649 -27.4400 5 C8y C 13.0649 -26.0400 6 C8x C 11.8524 -25.3400 7 X Cl 14.2960 -28.1510 8 C1c C 14.2960 -25.3290 9 O7a O 15.5012 -26.0247 10 C1b C 14.2957 -23.9401 11 C7a C 16.6835 -25.3419 12 N1a N 17.8775 -26.0312 13 O6a O 16.6835 -23.9402 14 N4y N 13.0714 -23.2334 15 N5x N 13.0557 -21.8404 16 C8x C 11.7275 -21.4260 17 N5x N 10.9229 -22.5612 18 N5x N 11.7539 -23.6772 BOND 19 1 1 2 2 2 2 3 1 3 3 4 2 4 4 5 1 5 5 6 2 6 1 6 1 7 4 7 1 8 5 8 1 9 8 9 1 #Down 10 8 10 1 11 9 11 1 12 11 12 1 13 11 13 2 14 10 14 1 15 14 15 1 16 15 16 2 17 16 17 1 18 17 18 2 19 14 18 1 |